 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi |
|
Intest Res. 2018;16(2):233-245. Published online April 30, 2018 DOI: https://doi.org/10.5217/ir.2018.16.2.233 |
|
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies Intestinal Research. 2018;16(3):499  Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies Intestinal Research. 2018;16(2):233 OC.06.1: Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in two Multinational, Phase 3 Clinical Trials Digestive and Liver Disease. 2017;49:e90-e91 One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 Alimentary Pharmacology & Therapeutics. 2012;37(2):204-213 Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis Inflammatory Intestinal Diseases. 2019;4(4):131-143 P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies Journal of Crohn's and Colitis. 2019;13(Supplement_1):S351-S352 Tu2003 Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis Gastroenterology. 2016;150(4):S1003 P519 Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials Journal of Crohn's and Colitis. 2023;17(Supplement_1):i646-i646 Mo1781 Tofacitinib Plasma Concentration Monitoring Is Not Needed for Optimization of Induction Therapy in Moderate to Severe Ulcerative Colitis: Results of Pooled Exposure-Response Analyses of Phase 3 Induction Studies Gastroenterology. 2016;150(4):S774 P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment Journal of Crohn's and Colitis. 2019;13(Supplement_1):S378-S379 |
